Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis

Author:Cerqueira, Joao   Berthele, Achim   Cree, Bruce   Filippi, Massimo   Pardo, Gabriel   Pearson, Owen   Traboulsee, Anthony   Ziemssen, Tjalf   Vollmer, Timothy   Bernasconi, Corrado   Mandel, Corey   Kulyk, Inessa   Chognot, Cathy   Schneble, Hans-Martin   Prajapati, Kalpesh   Havrdova, Eva   

Session Name:S46: MS Therapeutics and Clinical Decision Making  

Topic:MS and Inflammatory Disease  

Program Number:S46.002  

Author Institution:2CA-Clinical Academic Centre Braga, Portugal Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal, Lisbon, Portugal  School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy  Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Morriston Hospital, Swansea, UK, Swansea, United Kingdom  University of British Columbia, Vancouver, BC, Canada, Vancouver, BC, Canada  Dresden University of Technology, Dresden, Germany, Dresden, Germany  University of Colorado Denver, Denver, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Genentech, Inc., San Francisco, CA, USA, South San Francisco, CA  IQVIA Solutions, Inc., Amsterdam, The Netherlands, Amsterdam, Netherlands  General University Hospital and Charles University, Prague, Czech Republic, Praha 2, Czech Republic